Reduction of regulatory T cells in skin lesions but not in peripheral blood of patients with systemic scleroderma

Annals of the Rheumatic Diseases

Volumn 70, Issue 8, 2011, Pages 1475-1481

  Klein, S ^a   Kretz, C C ^a   Ruland, V ^b   Stumpf, C ^a   Haust, M ^c   Hartschuh, W ^d   Hartmann, M ^d   Enk, A ^d   Suri Payer, E ^a   Oberle, N ^a   Krammer, P H ^a   Kuhn, Annegret ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LICHEN PLANUS; LYMPHOCYTE PROLIFERATION; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PSORIASIS; REGULATORY T LYMPHOCYTE; RODNAN SKIN SCORE; SCORING SYSTEM; SKIN BIOPSY; SYSTEMIC SCLEROSIS;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; DERMATITIS; DERMATOLOGIC AGENTS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; RECEPTOR, ENDOTHELIN A; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SKIN; SULFONAMIDES; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 79959798607     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.116525     Document Type: Article

References (44)

1. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German Network for Systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology (Oxford) 2008;47:1185-92. (Pubitemid 352038224)
2. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5. (Pubitemid 18073738)
3. Kowal-Bielecka O, Landewé R, Avouac J, et al. 2. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8.
4. Hunzelmann N, Moinzadeh P, Genth E, et al. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther 2009;11:R30.
5. Ong VH, Denton CP. Innovative therapies for systemic sclerosis. Curr Opin Rheumatol 2010;22:264-72.
6. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-23. (Pubitemid 32971843)
7. Denton CP, Pope JE, Peter HH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis 2008;67:1222-8.
8. Heresi GA, Minai OA. Bosentan in systemic sclerosis. Drugs Today 2008;44:415-28.
9. Hettema ME, Zhang D, Bootsma H, et al. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 2007;66:1398-9. (Pubitemid 47492490)
10. Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93. (Pubitemid 39643947)
11. Kuhn A, Haust M, Ruland V, et al. Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial. Rheumatology (Oxford) 2010;49:1336-45.
12. Kabunga P, Coghlan G. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma. Drugs 2008;68:1635-45.
13. Hunzelmann N, Krieg T. Scleroderma: from pathophysiology to novel therapeutic approaches. Exp Dermatol 2010;19:393-400.
14. Suri-Payer E, Fritzsching B. Regulatory T cells in experimental autoimmune disease. Springer Semin Immunopathol 2006;28:3-16. (Pubitemid 44267954)
15. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998;188:287-96. (Pubitemid 28357757)
16. Lindley S, Dayan CM, Bishop A, et al. Defective suppressor function in CD4(+) CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005;54:92-9. (Pubitemid 40105099)
17. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002;109:131-40. (Pubitemid 34052549)
18. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-9. (Pubitemid 38481088)
19. Bonelli M, Savitskaya A, von Dalwigk K, et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int Immunol 2008;20:861-8. (Pubitemid 351876312)
20. Lyssuk EY, Torgashina AV, Soloviev SK, et al. Reduced number and function of CD4+CD25highFoxP3+ regulatory T cells in patients with systemic lupus erythematosus. Adv Exp Med Biol 2007;601:113-19.
21. Franz B, Fritzsching B, Riehl A, et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007;56:1910-20. (Pubitemid 47110390)
22. Cools N, Ponsaerts P, Van Tendeloo VF, et al. Regulatory T cells and human disease. Clin Dev Immunol 2007;2007:89195.
23. Costantino CM, Baecher-Allan CM, Hafler DA. Human regulatory T cells and autoimmunity. Eur J Immunol 2008;38:921-4.
24. Dejaco C, Duftner C, Grubeck-Loebenstein B, et al. Imbalance of regulatory T cells in human autoimmune diseases. Immunology 2006;117:289-300.
25. Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 2008;133:775-87. (Pubitemid 351707693)
26. Kuhn A, Beissert S, Krammer PH. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus. Arch Dermatol Res 2009;301:71-81.
27. Radstake TR, van Bon L, Broen J, et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFbeta expression. PLoS One 2009;4:e5981.
28. Slobodin G, Ahmad MS, Rosner I, et al. Regulatory T cells (CD4(+)CD25(bright) FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010;261:77-80.
29. Antiga E, Quaglino P, Bellandi S, et al. Regulatory T cells in the skin lesions and blood of patients with systemic sclerosis and morphoea. Br J Dermatol 2010;162:1056-63.
30. Clements P, Lachenbruch P, Siebold J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-5.
31. Furst DE, Clements PJ, Steen VD, et al. The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998;25:84-8. (Pubitemid 28060123)
32. Iannone F, Riccardi MT, Guiducci S, et al. Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension. Ann Rheum Dis 2008;67:1121-6.
33. Sumner MJ, Cannon TR, Mundin JW, et al. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol 1992;107:858-60.
34. Haas J, Hug A, Viehöver A, et al. Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005;35:3343-52. (Pubitemid 41672538)
35. Cohen JL, Boyer O. The role of CD4+CD25hi regulatory T cells in the physiopathogeny of graft-versus-host disease. Curr Opin Immunol 2006;18:580-5. (Pubitemid 44322035)
36. Kriegel MA, Lohmann T, Gabler C, et al. Defective suppressor function of human CD4+CD25+ regulatory T cells in autoimmune polyglandular syndrome type II. J Exp Med 2004;199:1285-91. (Pubitemid 38620265)
37. Valencia X, Stephens G, Goldbach-Mansky R, et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006;108:253-61. (Pubitemid 43990636)
38. Gu YS, Kong J, Cheema GS, et al. The immunobiology of systemic sclerosis. Semin Arthritis Rheum 2008;38:132-60.
39. de Boer OJ, van der Loos CM, Teeling P, et al. Immunohistochemical analysis of regulatory T cell markers FOXP3 and GITR on CD4+CD25+ T cells in normal skin and inflammatory dermatoses. J Histochem Cytochem 2007;55:891-8. (Pubitemid 47293835)
40. de Boer OJ, van der Meer JJ, Teeling P, et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS ONE 2007;2:e779.
41. Badea I, Taylor M, Rosenberg A, et al. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology (Oxford) 2009;48:213-21.
42. Leitenberger JJ, Cayce RL, Haley RW, et al. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases. Arch Dermatol 2009;145:545-50.
43. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 2005;44:274-9. (Pubitemid 40361280)
44. Loser K, Beissert S. Dendritic cells and T cells in the regulation of cutaneous immunity. Adv Dermatol 2007;23:307-33.